CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
-8.73%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$2.56B
AUM Growth
+$2.56B
(-26%)
Cap. Flow
-$400M
Cap. Flow
% of AUM
-15.58%
Top 10 Holdings %
Top 10 Hldgs %
43.81%
Holding
134
New
13
Increased
7
Reduced
67
Closed
28
Top Buys
| 1 |
Monte Rosa Therapeutics
GLUE
|
$69.6M |
| 2 |
Biomea Fusion
BMEA
|
$48.4M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$47M |
| 4 |
JBIO
Jade Biosciences, Inc. Common Stock
JBIO
|
$44.6M |
| 5 |
VERV
Verve Therapeutics
VERV
|
$40.6M |
Top Sells
| 1 |
C4 Therapeutics
CCCC
|
$80.8M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$64.2M |
| 3 |
Novavax
NVAX
|
$45.3M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$43.6M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$32.8M |
Sector Composition
| 1 | Healthcare | 99.14% |
| 2 | Financials | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Nuvation Bio
NUVB
$1.08B
| – | – |
-234,445
| Closed | -$2.45M |
|
|
127
Novavax
NVAX
$1.2B
| – | – |
-250,000
| Closed | -$45.3M |
|
128
Replimune Group
REPL
$460M
| – | – |
-125,000
| Closed | -$3.81M |
|
129
SPDR S&P Biotech ETF
XBI
$5.29B
| – | – |
0
| – | – |
|
|
GRCL
130
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| – | – |
-125,000
| Closed | -$1.93M |
|
|
PNT
131
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| – | – |
-500,000
| Closed | -$5.26M |
|
|
ALBO
132
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| – | – |
-500,000
| Closed | -$17.6M |
|
|
BLSA
133
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| – | – |
-500,000
| Closed | -$5.29M |
|
|
CCXI
134
DELISTED
ChemoCentryx, Inc.
CCXI
| – | – |
-850,000
| Closed | -$43.6M |
|